Investor News

On November 14th Medistim announced the launch of the PATENT study, an open, prospective, multicenter trial aimed at evaluating the immediate clinical benefits and long-term prognostic value of intraoperative completion control using transit time flow measurement (TTFM) and high-frequency ultrasound (HFUS) imaging.

The company is pleased to announce the successful completion of its Early Access program for the new MiraQ™ INTUI software platform. The official product launch is set for December 13 at the International Coronary Congress (ICC) in London.

Medistim to host Capital Markets Day 2024

After years of preparation, Medistim has successfully obtained its first CE certificates under the latest EU Medical Device Regulation (EU MDR 2017/745).

This move is part of the company's ongoing commitment to providing exceptional service to customers as well as fulfilling the company’s global growth strategy. The company is well positioned to continue its growth by further…

Medistim is pleased to announce its partnership with ROMA-Women, a groundbreaking cardiac surgery trial that is specifically focused on women. Historically, cardiovascular research and treatment protocols have primarily focused on men, leaving women underrepresented in…